BioAlliance Pharma Signs Collaborative Agreement With Vaccine Leader
BioAlliance Pharma SA recently announced a collaboration agreement with one of the world-leading vaccine companies to develop a vaccine application of its Lauriad mucoadhesive technology. The terms of this agreement are not disclosed at this time.
This research program aims at establishing the feasibility of using Lauriad technology for vaccination, leading to an efficient needle-free administration based on the application to the gum of this mucoadhesive tablet containing a vaccine antigen. Moreover, this would also avoid the constraints related to manufacturing sterile injectable forms.
This project is carried out within the Fluriad consortium set in March 2011, co-labeled by both Clusters of Excellence Medicen Paris Region and Atlanpole Biotherapies and financed by the Fond Unique Interministériel (a French program supporting collaborative research projects).
“This collaboration with one of the world-leading vaccine companies shows the potential interest of our innovative Lauriad system for a needle-free vaccination. This is also a major step taken to increase the value of our proprietary Lauriad technology, already validated through three major products of our portfolio: Loramyc and Sitavig, already registered, and Validive, in Phase II clinical development,” said Judith Greciet, CEO of BioAlliance Pharma. “A first successful feasibility would open the way to promising new opportunities in vaccine field with significant market potential worldwide.”
Dedicated to cancer and supportive care treatment with a focus on resistance targeting and orphan products, BioAlliance conceives and develops innovative products for specialty markets especially in the hospital setting and for orphan or rare diseases. For more information, visit www.bioalliancepharma.com.
Total Page Views: 873
